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Capecitabine and docetaxel have single-agent activity in upper gastrointestinal tumours, and have together demonstrated preclinical
synergy and a survival benefit in breast cancer, and high response rates in first-line metastatic gastric cancer. This trial assessed the
efficacy, safety and feasibility of capecitabine in combination with docetaxel in patients with metastatic oesophageal cancer. In all, 24
patients with advanced disease (17 squamous cell carcinoma and seven adenocarcinoma) received oral capecitabine (1000mgm
 2
twice daily on days 1–14) plus intravenous docetaxel (75mgm
 2 on day 1) every 3 weeks as first- (n¼16) or second-line (n¼8)
therapy. Patients received a median of four cycles of treatment (range, 0–6). The median follow-up is 16.5 months (range, 7.9–21.4
months). Intent-to-treat efficacy analysis showed an overall response rate of 46%. Of the 11 responders (one complete and 10
partial), nine of 16 (56%) received first-line and two of eight (25%) received second-line therapy. The median time to progression was
6.1 months (95% confidence interval (CI), 4.5–7.7 months). The meian survival was 15.8 months (95% CI, 7.8–23.9 months). Severe
adverse events (grade 3/4) reported were: neutropenia (42%, including febrile neutropenia 8%), hand-foot syndrome (29%),
diarrhoea (13%), sensory neuropathy (13%), anaemia (8%) and fatigue (8%). Capecitabine plus docetaxel has a manageable adverse
event profile and very promising activity in metastatic oesophageal cancer, at least comparable to other doublet regimens. Therefore,
the combination merits further investigation in this setting.
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The incidence of oesophageal cancer is increasing (Blot et al, 1991)
and because of early lymphogenic and haematogeneous spread,
most patients are diagnosed with advanced disease. Unfortunately,
patients with recurrent or metastatic disease are incurable, and
palliative therapy with chemotherapeutic agents is the primary
treatment option. During the last decade, numerous chemother-
apeutic agents, such as cisplatin, 5-fluorouracil (5-FU), mitomycin
C, irinotecan, vinorelbine and paclitaxel, have been evaluated in
patients with oesophageal cancer. However, complete responses
are rare, responses are usually of a short duration with a median
survival of only 6–10 months (Iizuka et al, 1992; Bleiberg et al,
1997; Enzinger et al, 1999; Hayashi et al, 2001) and adverse effects,
especially with cisplatin-based regimens, are often substantial.
Thus, there is an urgent need for tolerable and active agents and
protocols for the treatment of oesophageal cancer.
Single-agent docetaxel has revealed only moderate activity in
patients with previously untreated adenocarcinoma of the upper
gastrointestinal tract (Einzig et al, 1996; Heath et al, 2002), but
combination regimens, for example, docetaxel plus irinotecan,
have been shown to induce remissions in oesophageal cancer
(Ilson et al, 1998, 1999; Lordick et al, 2003). Capecitabine is an
oral fluoropyrimidine designed to generate 5-FU preferentially
in tumour tissue while minimising systemic 5-FU exposure. After
absorption, capecitabine is metabolised to 5-FU by a three-step
process, the final step of which is mediated by thymidine
phosphorylase (TP). Tumour selectivity results from the signifi-
cantly greater activity of TP in tumours compared with healthy
tissue (Miwa et al, 1998; Schu ¨ller et al, 2000). Taxanes result in the
upregulation of TP in tumour tissue (Sawada et al, 1998), which
appears to further enhance tumour sensitivity to capecitabine.
Indeed, coadministration of capecitabine and taxanes exhibits
synergistic antitumour activity in preclinical studies (Sawada et al,
1998; Ishitsuka, 2000). Clinically, oral capecitabine is approved and
is used widely in the management of metastatic breast and
colorectal cancers (Blum et al, 1999; Van Cutsem et al, 2000). As
first-line therapy for metastatic colorectal cancer, capecitabine
results in superior response rates, improved tolerability and
greater convenience compared with 5-FU/LV (Mayo Clinic regi-
men) (Hoff et al, 2001; Van Cutsem et al, 2001, 2004). In pretreated
metastatic breast cancer, adding capecitabine to docetaxel provides
clear benefits in terms of response rates, time to disease
progression and overall survival over single-agent docetaxel
(O’Shaughnessy et al, 2002). The combination of capecitabine
and taxanes has also been shown to be active as first-line treatment
in phase II studies in patients with unresectable or metastatic
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sgastric cancer (Kang et al, 2004; Kim et al, 2004). The safety
profiles of capecitabine and taxanes do not appear to overlap and
the combination of oral capecitabine plus docetaxel every 3 weeks
can be conveniently administered as home-based therapy. Hence,
we performed a phase II trial to investigate the efficacy, safety
and feasibility of the combination of capecitabine and docetaxel in
patients with incurable adenocarcinoma or squamous cell
carcinoma of the oesophagus. As this combination was associated
with a high rate of neutropenic fever in a previous study
(O’Shaughnessy et al, 2002), we evaluated a 3-weekly regimen of
capecitabine plus docetaxel at doses of 1000mgm
 2 twice daily
on days 1–14 and 75mgm
 2 intravenously (i.v.) on day 1,
respectively.
MATERIALS AND METHODS
Patient population
Patients with histologically confirmed adenocarcinoma or squa-
mous cell carcinoma of the oesophagus or gastro-oesophageal
junction were enrolled at a single site (Klinikum rechts der Isar,
Technical University of Munich, Germany). The patients had to
fulfil specific inclusion criteria in order to be entered on the study.
To be eligible, patients had to have metastatic disease with at least
one bidimensionally measurable lesion X1cm by CT scan or MRI,
taken after oral and i.v. contrast, and be either chemotherapy-
naive or previously treated with no more than one chemotherapy
regimen. Patients had to be 418 years of age with an Eastern
Cooperative Oncology Group (ECOG) performance status p2 and
a life expectancy of X12 weeks. Adequate bone marrow, renal and
hepatic function was necessary and was defined as an absolute
neutrophil count X1.5 l0
91
 1, platelets X100 10
9l
 1, serum
creatinine o1.5 upper limit of normal (ULN), total bilirubin
p1.5 ULN, SGOT and/or SGPT p1.5 ULN (p5.0 ULN in the
presence of liver metastases). Patients were excluded if they had
CNS metastases or neuropathy Xgrade 2, as were women who
were pregnant or lactating.
Complete history and physical examination, laboratory tests, CT
scans of all tumour-involved areas and ECG were performed before
study entry. Pregnancy testing was performed in women of
childbearing age. All patients gave written, informed consent
before enrolment and the study was approved by the ethics
committee for human research at the Technical University of
Munich. The study conformed to the principles of the Declaration
of Helsinki and its subsequent amendments.
Treatment plan
Oral capecitabine was administered at a dose of 1000mgm
 2 twice
daily on days 1–14 every 3 weeks. Docetaxel was administered at a
dose of 75mgm
 2 i.v. on day 1 every 3 weeks. Docetaxel was given
1h before the first oral dose of capecitabine. Docetaxel was
administered over 60min in 500ml saline solution. Oral dexa-
methasone (8mg) was given as antiemetic prophylaxis 30min
prior to the infusion of docetaxel.
Patients underwent follow-up CT scans for assessment of
response after every two cycles of therapy. Tumour response was
classified on the basis of the response evaluation criteria defined
by RECIST guidelines (Therasse et al, 2000). Responses were
reviewed by independent radiologists at the Department of
Radiology of the Klinikum Rechts der Isar, and were confirmed
after at least 4 weeks. Patients were treated until best response or
until there was evidence of disease progression, unacceptable
adverse events, patient withdrawal or death. Patients were seen
every week in the outpatient clinic for laboratory tests and safety
evaluation, which was determined using the National Cancer
Institute Common Toxicity Criteria (NCI-CTC, version 3.0).
Statistical considerations
The primary end point of the study was to determine the
proportion of patients responding to capecitabine plus docetaxel.
The study was designed as a two-stage trial according to Gehan
(1961), assuming a response rate of 30%. With a power of 90%, this
resulted in a sample size of seven patients for the first stage. The
size of the second stage was determined by the observed number of
responses and by the prespecified precision of 10%. There were
three responders during the first stage of the study. Therefore,
according to the study design, the sample size for the whole study
was extended to 24 patients. All eligible patients were included in
the response, safety and survival analyses. The survival analysis
was performed using SPSS software (version 12.0). Confidence
intervals (CIs) (95%) were calculated for all relevant estimates
using StatXact (version 5).
RESULTS
Patient baseline characteristic
A total of 24 patients were enrolled between February 2003 and
April 2004. Patient baseline characteristics are listed in Table 1. Six
(25%) of the patients had undergone oesophagectomy and half of
the patients received prior radiation therapy. Of the 24 patients,
16 (67%) were chemotherapy-naive and the remaining eight (33%)
had received prior chemotherapy for metastatic disease. Prior
chemotherapeutic regimens mostly comprised 5-FU and platinum
compound combinations. Although patients with reduced perfor-
mance status (ECOG score 2) were eligible to enter the study
according to the inclusion criteria, all of the treated patients were
in good physical condition (ECOG scores 0 and 1).
Most of the patients had squamous cell carcinoma (71%), with
lymph nodes (79%) as the main site of metastases. Other
predominant sites of metastases were the lung (37%) and the
liver (29%).
Efficacy analysis
Patients completed a median of four cycles (range 0–6) of
treatment. Response analysis included all of the 24 patients
Table 1 Patient baseline characteristics
Characteristic No. %
Age (years)
Median 61.5
Range 49–72
Gender
Male 21 88
Female 3 12
ECOG performance status
08 3 3
11 6 6 7
Histology
Adenocarcinoma 7 29
Squamous cell carcinoma 17 71
Previous treatment
Oesophagectomy 6 25
First-line chemotherapy 8 33
Radiotherapy 3 12
Chemoradiotherapy 9 37
ECOG¼Eastern Cooperative Oncology Group.
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senrolled (intent-to-treat (ITT) population). Tumour response was
evaluable according to RECIST criteria in 22 patients. Two other
patients did not complete two cycles of chemotherapy, as they died
before the first tumour assessment was carried out. An objective
overall response was seen in 11 patients, that is, the objective
response rate (ORR) was 46% (95% CI, 26–67%). There was one
complete remission (CR) and 10 patients achieved partial
remission (PR). Four patients had stable disease (SD) and seven
patients had disease progression, primarily during the first two
cycles of treatment (Table 2). The response rates in patients with
no previous chemotherapy (first-line) and with previous chemo-
therapy (second-line) were 56% (nine of 16 (95% CI, 28–84%))
and 25% (two of eight (95% CI, 15–35%)), respectively.
The tumour control rate (ORRþSD) appeared to be associated
with the two histological subtypes of oesophageal cancer: 69% (11
of 16) in patients with squamous cell carcinomas and 50% (three of
six) in patients with adenocarcinomas. Notably, we discovered that
three out of the eight patients treated second-line had adenocarci-
nomas of the oesophagus, and these patients were eventually
determined to be nonresponders.
The median time to disease progression was 6.1 months (95%
CI, 4.5–7.7 months, Figure 1). Overall survival of the 24 evaluable
patients is shown in Figure 2. With a median follow-up duration of
13.4 months, the median survival time was 15.8 months (95% CI,
7.8–23.9 months). To date, 12 of the 24 patients (50%) are alive,
with a median follow-up of 16.5 months (range, 7.9–21.4 months).
As would be expected, median survival was longer in those who
received docetaxel/capecitabine as first-line therapy (15.8 months
(95% CI, 9.5–22.1 months)) compared with those treated in the
second-line setting (6.2 months (95% CI, 3.5–8.8 months),
Figure 3).
Safety
Major and minor treatment-related adverse events are summarised
in Table 3. Treatment was generally well tolerated in the majority
of patients, with few severe adverse events. The mortality rate
within the first 60 days of therapy was 8%. One patient died
because of rapid tumour progression with gastrointestinal bleeding
and one because of oesophageal stent perforation with subsequent
mediastinitis. These early deaths were not considered to be
treatment induced.
Grade 3/4 adverse events included neutropenia (42%), hand–
foot syndrome (29%), diarrhoea (13%), sensory neuropathy (13%),
fatigue (8%) and anaemia (8%). No episodes of grade 3/4 nausea,
vomiting, stomatitis, and thrombocytopenia were reported during
the study. The most common haematological toxicity of docetaxel
on this schedule was neutropenia. Of the 10 (42%) patients with
grade 3/4 neutropenia, two (8%) experienced febrile neutropenia
with subsequent in-patient hospitalisation. The most severe
nonhaematological adverse event was grade 3 hand–foot syn-
drome in seven patients (29%), resulting in dose reductions of
capecitabine in four patients (17%) as symptoms worsened over
time. Owing to adverse events, dose adjustments for one or both
agents (to o80% of initial doses) were reported in 41% of patients.
DISCUSSION
The present study was undertaken to assess the efficacy and safety
of combining docetaxel with capecitabine in patients with
incurable adenocarcinoma or squamous cell carcinoma of the
oesophagus. With an ORR of 46% and an encouraging median
survival of 15.8 months, this regimen compares favourably to other
previously investigated combinations. The response rate of 56%
observed in chemotherapy-naive patients is comparable to
Table 2 Antitumour efficacy (ITT analysis, n¼24)
Type of response No. % 95% CI
ORR 11 46 26–67
CR 1 4 0.1–21
PR 10 42 22–63
SD 4 17 5–37
Progressive disease 7 29 13–51
Not evaluable 2 8 1–27
ITT¼intent-to-treat; CI¼confidence interval; ORR¼objective response rate;
CR¼complete response; PR¼partial response; SD¼stable disease.
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Figure 1 Kaplan–Meier plot of time to disease progression for all
patients treated for metastatic oesophageal cancer.
1.0
0.8
0.6
0.4
0.2
0
0 5 10 15 20 25
Time (months)
P
r
o
b
a
b
i
l
i
t
y
Censored
Figure 2 Kaplan–Meier plot of overall survival for all patients treated for
metastatic oesophageal cancer.
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sresponses obtained with the commonly used combination of
cisplatin plus 5-FU or the weekly treatment regimen of cisplatin
and irinotecan (Ilson et al, 1999). As the toxicity induced by
cisplatin-based chemotherapy, particularly in the palliation of
metastatic disease, is often substantial, the combination of
capecitabine and docetaxel seems to be an effective and feasible
alternative to the standard cisplatin-based regimens for metastatic
oesophageal cancer, but with less toxicity/side effects.
The results of the current study are also supported by the
preliminary data of a phase II Korean study evaluating a similar
regimen of capecitabine (1000mgm
 2 twice daily on days 1–14)
and docetaxel (36mgm
 2 on days 1 and 8) every 3 weeks in
patients with untreated metastatic gastric cancer (Kim et al, 2004).
In that study, the ORR was 40% and median survival was 12.0
months, which is similar to that observed in the current study. In
contrast to our study, where most of the patients had squamous
cell carcinoma, most of the patients in the Korean study had
adenocarcinoma. Nevertheless, all patients included in our study
with adenocarcinoma and who were previously untreated (four of
24) were classified as responders. Another phase II study, which
evaluated the activity and feasibility of first-line capecitabine
(825mgm
 2 twice daily on days 1–14) plus paclitaxel (175mgm
 2
on day 1) every 3 weeks in advanced gastric cancer, showed similar
results to ours, with an ORR of 53% and a median survival of 14.6
months (Kang et al, 2004). In contrast to the above-mentioned
trials, which found the taxane–capecitabine combination to be
active in oesophagogastric adenocarcinoma, the current data show
for the first time the clinical efficacy of docetaxel/capecitabine in
squamous cell carcinomas of the oesophagus.
While there are some promising treatment options with
encouraging response and survival data in first-line metastatic
oesophageal cancer, there is still a lack of effective treatment
options for patients who have relapsed after a cisplatin-containing
regimen. In patients with pretreated oesophageal cancer, the
reported response rates vary between 0 and 16% (Conroy et al,
1996; Heath et al, 2002; Lordick et al, 2003; Muro et al, 2004).
In our study, the response rate of 25% in patients with prior
chemotherapy was encouraging compared to findings reported
from other second-line trials. Single-agent docetaxel in pretreated
patients revealed only a moderate response rate of 16% (Muro
et al, 2004). Another trial reported that therapy with docetaxel was
completely ineffective in oesophageal adenocarcinoma (Heath
et al, 2002). However, the ability to interpret the findings from
these single-agent docetaxel studies is limited by their small
sample size (no25). It is also important to acknowledge this same
limitation in our study, with only eight patients receiving the
docetaxel/capecitabine combination regimen as second-line therapy.
While there is presently no standard second-line treatment for
metastatic oesophageal cancer, the combination of capecitabine
plus docetaxel might be an option for patients who are very keen to
receive treatment.
The relative absence of grade 3/4 adverse events other than
neutropenia and hand–foot syndrome seen in this trial was
remarkable. Furthermore, there were no treatment-related deaths.
Grade 3/4 neutropenia was the most common and severe adverse
event and was observed in almost half of the patients, but only two
patients (8%) developed febrile neutropenia. Similar haematolo-
gical toxicities were described in other phase II studies with the
combination of capecitabine and a taxane (Kang et al, 2004; Kim
et al, 2004). In contrast, capecitabine plus docetaxel combination
resulted in a 16% rate of neutropenic fever in second-line
metastatic breast cancer (O’Shaughnessy et al, 2002). Conse-
quently, in our study the dose of capecitabine was a priori reduced
to 80% of the dose used in the metastatic breast cancer trial.
Nonhaematological adverse events occurred in relatively few
patients and were generally acceptable. The most frequently
reported event was grade 3/4 hand–foot syndrome, affecting every
third patient, which was a similar rate reported by O’Shaughnessy
et al. This side effect was manageable with transient capecitabine
interruptions or dose modifications in the majority of patients.
Gastrointestinal side effects, such as diarrhoea, nausea and
vomiting, which were also anticipated with the combination,
occurred less frequently than usually seen with standard dose
capecitabine single-agent therapy (Scheithauer et al, 2003). These
side effects were readily managed with appropriate medical
interventions, for example, loperamide and rehydration for
diarrhoea and 5-HT3 receptor antagonists and dexamethasone
for nausea and emesis. Consistent with the known toxicities of
docetaxel, neurological adverse effects occurred in a relatively
high proportion of patients, although sensory neuropathy was
predominantly mild to moderate in intensity. Severe grade 3/4
neurotoxicity was only reported in three patients. Generally, the
combination regimen of capecitabine and docetaxel has a manage-
able safety profile, consistent with the known adverse events
associated with the individual agents. Nevertheless, myelosuppres-
sion demands careful patient management.
In conclusion, capecitabine and docetaxel is an effective and
feasible combination in the first-line treatment of metastatic
oesophageal cancer and is also a promising regimen in pretreated
patients. Unfortunately, the small sample size of this trial does not
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Figure 3 Kaplan–Meier plot of overall survival according to line of
treatment for metastatic oesophageal cancer.
Table 3 Most common treatment-related adverse events
Grade 1/2 Grade 3/4
Toxicity No. % No. %
Anaemia 9 37 2 8
Neutropenia 3 12 10 42
Febrile neutropenia 0 0 2 8
Diarrhoea 3 12 3 13
Sensory neuropathy 7 29 3 13
Fatigue 9 37 2 8
Hand–foot syndrome 7 29 7 29
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sallow any definitive conclusions to be made about the efficacy of
this combination regimen. Thus, further investigation in larger
groups of patients is warranted to compare capecitabine plus
docetaxel with other standard first-line chemotherapy regimens in
a randomised trial and to confirm the efficacy of second-line
treatment in adenocarcinoma and squamous cell carcinomas of the
oesophagus.
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